Related Experiment Videos
Designing inhibitors of cyclin-dependent kinases
Ian R Hardcastle1, Bernard T Golding, Roger J Griffin
1Northern Institute for Cancer Research University of Newcastle upon Tyne, Newcastle upon Tyne, NE1 4RU, United Kingdom. I.R.Hardcastle@ncl.ac.uk
Abstract:
Cyclin-dependent kinases (cdks) play a pivotal role in controlling progression through the cell cycle. The complex mechanisms that control cdks have been elucidated and, in the case of cdk2, explained with reference to X-ray crystal structures of the catalytically active and inactive kinase. Deregulation of the cell cycle is commonly observed in cancer, so cdks are potential targets for experimental therapeutic agents. A number of distinct structural classes of cdk inhibitors have been discovered. Good selectivity among these ATP competitive inhibitors for cdks over other kinases has been established, and selectivity between individual cdks is often observed. The crystal structures of a number of key inhibitors bound to cdk2 can be used to explain the observed structure-activity relationships within the compound series and to guide the design of more potent inhibitors.
Insights
Cyclin-dependent kinases (CDKs) regulate cell cycle progression. CDK inhibitors show promise as cancer therapeutics, with structural studies guiding the design of more potent and selective drugs.
Area of Science:
- Biochemistry and Molecular Biology
- Cell Biology
- Medicinal Chemistry
Background:
- Cyclin-dependent kinases (CDKs) are crucial regulators of the cell cycle.
- Cell cycle deregulation is a hallmark of cancer, making CDKs attractive therapeutic targets.
- Understanding CDK mechanisms is key to developing novel cancer treatments.
Purpose of the Study:
- To elucidate the complex regulatory mechanisms of CDKs, focusing on CDK2.
- To explain CDK inhibitor structure-activity relationships (SAR) using X-ray crystallography.
- To guide the design of more potent and selective CDK inhibitors for cancer therapy.
Main Methods:
- X-ray crystallography of CDK2 in active and inactive states.
- Analysis of distinct structural classes of ATP-competitive CDK inhibitors.
- Structure-activity relationship (SAR) studies of inhibitor binding to CDK2.
Main Results:
- Elucidation of CDK regulatory mechanisms, particularly for CDK2, via crystal structures.
- Discovery of distinct structural classes of CDK inhibitors with good selectivity over other kinases.
- Observed selectivity between individual CDK isoforms for certain inhibitors.
Conclusions:
- CDK inhibitors represent a promising class of experimental therapeutic agents for cancer.
- Crystal structures of inhibitors bound to CDK2 explain SAR and aid in rational drug design.
- Targeting CDKs offers a viable strategy for developing novel anti-cancer drugs.